PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
Summary
- Broad labeling inclusive of all disease subtypes for individuals 1 month of age and older - - PTC will host a conferen...
- Broad labeling inclusive of all disease subtypes for individuals 1 month of age and older - - PTC will host a conference call on Monday, July 28 th at 5:00 pm ET - WARREN, N.J. , July 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has approved SEPHIENCE™ (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU).
Tags
PTC